SEC Comment Letter 0000000000-24-003085 to Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI)
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: March 21, 2024 · CIK: 0001503802 · Accession: 0000000000-24-003085
AI Filing Summary & Sentiment
File numbers found in text: 001-36167
Letter
United States securities and exchange commission logo March 21, 2024 Michael Mason EVP, Chief Financial Officer and Treasurer Karyopharm Therapeutics Inc. 85 Wells Ave., 2nd Floor Newton, MA 02459 Re:Karyopharm Therapeutics Inc. Form 10-K for the year ended December 31, 2023 Filed February 29, 2024 File No. 001-36167 Dear Michael Mason: We have limited our review of your filing to the financial statements and related disclosures and have the following comment(s). Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K filed February 29, 2024 Management's Discussion and Analysis of Financial Condition and Results of Operations, page 1.Please revise your future filings to address the following: •Revise to clearly disclose the extent to which you track any of your research and development (R&D) expenses on a program-by-program basis. •To the extent you track any R&D expenses by program, revise to separately quantify those amounts. •Please provide us with your proposed disclosures. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Sasha Parikh at 202-551-3627 or Kevin Vaughn at 202-551-3494 with any questions.
FirstName LastNameMichael Mason Comapany NameKaryopharm Therapeutics Inc. March 21, 2024 Page 2 FirstName LastName Michael Mason Karyopharm Therapeutics Inc. March 21, 2024 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
March 21, 2024
Michael Mason
EVP, Chief Financial Officer and Treasurer
Karyopharm Therapeutics Inc.
85 Wells Ave., 2nd Floor
Newton, MA 02459
Re:Karyopharm Therapeutics Inc.
Form 10-K for the year ended December 31, 2023
Filed February 29, 2024
File No. 001-36167
Dear Michael Mason:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment(s).
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K filed February 29, 2024
Management's Discussion and Analysis of Financial Condition and Results of Operations, page
99
1.Please revise your future filings to address the following:
•Revise to clearly disclose the extent to which you track any of your research and
development (R&D) expenses on a program-by-program basis.
•To the extent you track any R&D expenses by program, revise to separately quantify
those amounts.
•Please provide us with your proposed disclosures.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Sasha Parikh at 202-551-3627 or Kevin Vaughn at 202-551-3494 with any
questions.
FirstName LastNameMichael Mason
Comapany NameKaryopharm Therapeutics Inc.
March 21, 2024 Page 2
FirstName LastName
Michael Mason
Karyopharm Therapeutics Inc.
March 21, 2024
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences